MAR |Interim Report, January – September 2019

Acarix finalized a rights issue to finance further market expansion
In September we announced a rights issue in order to be able to further develop our
product offering and to intensify our international investments. During this period, I had
the opportunity to present Acarix at a large number of events, creating interest and
increased awareness of our company and unique CADScor®System.


Acarix Interim report Jan-Sep 2019

Acarix Delårsrapport jan-sep 2019


About Acarix
Acarix is a Swedish medical device company that innovates solutions for rapid AI-based rule out of Coronary Artery Disease (CAD). The CE approved and FDA DeNovo cleared Acarix CADScor®System is intended for patients experiencing chest pain with suspected CAD and designed to help reduce millions of unnecessary, invasive and costly diagnostic procedures. The CADScor system calculates a patient-specific CAD-score non-invasively in less than10 minutes and can help rule out more than one third of patients with at least 96% certainty of not being sick (in a population with approx. 10% CAD prevalence). Acarix is listed on the Nasdaq First North Premier Growth Market (ticker: ACARIX). Redeye AB (+46 (0)8 121 576 90, is Certified Advisor of Acarix.

For more information, please visit